(3alpha,5alpha,12alpha)-3,12-二羟基胆烷-24-酸 | 1912-55-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: (3alpha,5alpha,12alpha)-3,12-二羟基胆烷-24-酸
• 英文名称: (3α,5α,12α)-3,12-dihydroxy-cholan-24-oic acid
• 英文别名: allo-deoxycholic acid；allodeoxycholic acid；deoxycholic acid；allo-DCA；3α.12α-dihydroxy-5α-cholanoic acid-(24)；3α.12α-Dihydroxy-5α-cholansaeure-(24)；(4R)-4-[(3R,5S,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
• CAS: 1912-55-6
• 化学式: C₂₄H₄₀O₄
• 分子量: 392.579
• InChiKey: KXGVEGMKQFWNSR-WFTUMUMQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3alpha,5alpha,12alpha)-3,12-二羟基胆烷-24-酸 在 chromium(VI) oxide 、 溶剂黄146 作用下， 生成 3.12-dioxo-5α-cholanoic acid-(24)
  参考文献：
  名称：

  Kishi, Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1936, vol. 238, p. 210,219

  摘要：

  DOI：
• 作为产物：
  描述：

  脱氧胆酸甲酯 在 盐酸 、 2-iodoxybenzoic acid 、 四磷十氧化物 、 氨 、 lithium 、 potassium tri-sec-butyl-borohydride 、 叔丁醇 作用下， 以 四氢呋喃 、 甲醇 、 氯仿 、 二甲基亚砜 、 甲苯 为溶剂， 反应 88.08h， 生成 (3alpha,5alpha,12alpha)-3,12-二羟基胆烷-24-酸
  参考文献：
  名称：

  A stereoselective synthesis of the allo-bile acids from the 5β-isomers

  摘要：

  The allo-bile acids are a subset of the family of steroidal detergents found in most vertebrates. Because there are no major biological feedstocks for isolation of the alto-bile acids, they must be synthesized from the abundant 5 beta-reduced isomers. Here we report a general set of methods for the synthesis of allo-bile acids from the corresponding 5-beta isomers demarcated by a selective C-3 oxidation, IBX unsaturation, and stereoselective saturation. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.05.140

文献信息

• Alhaique; Giacomello; Giardina, Farmaco, Edizione Scientifica, 1967, vol. 22, # 8, p. 651 - 655
  作者：Alhaique、Giacomello、Giardina、Riccieri

  DOI：——

  日期：——
• METHOD FOR DETERMININGIN VITRO
  申请人：Clayton Pharmaceuticals LLC

  公开号：EP3423829A1

  公开（公告）日：2019-01-09
• METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD)
  申请人：Clayton Pharmaceuticals LLC

  公开号：EP3423829B1

  公开（公告）日：2020-10-28
• STEROID COMPOUNDS AS TREG MODULATORS AND USES THEREOF
  申请人：New York University

  公开号：US20210347811A1

  公开（公告）日：2021-11-11

  Steroid compounds are disclosed that have a formula represented by the following: (I) and wherein R 1 , R 2 , R 3a , R 3b , R 4a , R 4b , R 5 , R 6a , R 6b , R 7 , R 8 , and n are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for promoting differentiation of T regulatory (Treg) lymphocytes, and for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, and graft-versus-host disease.
• US9989519B1
  申请人：——

  公开号：US9989519B1

  公开（公告）日：2018-06-05